Communiqués Corcept Therapeutics Incorporated

Actions

CORT

US2183521028

Produits pharmaceutiques

Temps réel estimé Cboe BZX 22:01:03 12/10/2026			Varia. 5j.	Varia. 1 janv.
119,30 ^USD	-1,56%		-0,74%	+248,07%

06/10	Un initié de Corcept Therapeutics a vendu des actions pour 2 906 601 dollars, selon un récent dépôt auprès de la Securities and Exchange Commission (SEC)	MT
06/10	Un initié de Corcept Therapeutics a vendu des actions pour 1 160 731 dollars, selon un récent dépôt auprès de la SEC	MT

Communiqués

24/09	Corcept Therapeutics Announces Planned Leadership Transition	AQ
23/09	Corcept Announces Planned Leadership Transition	BU
18/09	Corcept annonce l'avis du CHMP recommandant l'autorisation de mise sur le marché de Lifyorli® (relacorilant) dans l'UE	BU
18/09	Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)	BU
29/07	Corcept: Q2 Earnings Snapshot	AQ
29/07	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update	BU
22/07	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call	BU
17/06	Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome	BU
17/06	Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm	NE
06/06	Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®	BU
29/05	Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure	BU
27/05	Corcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome	BU
30/04	Corcept: Q1 Earnings Snapshot	AQ
30/04	Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis	BU
30/04	Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update	BU
23/04	Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call	BU
22/04	Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026	AQ
21/04	Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026	BU
18/04	Corcept 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Corcept Therapeutics Incorporated - CORT	BU
13/04	Corcept présente les données complètes de l'essai pivot ROSELLA dans le cadre d'une présentation de dernière minute au congrès de la SGO, avec une publication simultanée dans The Lancet : Lifyorli™ (rélacorilant) plus nab-paclitaxel améliore la…	BU
10/04	Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer	BU
04/04	Corcept Therapeutics Incorporated Class Action Reminder – Robbins LLP Encourages CORT Stockholders to Contact the Firm for Information About Their Rights	BU
30/03	Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session	AQ
28/03	Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session	BU
25/03	FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer	BU